Last edition
News about "Non-Small Cell Lung Cancer "
CStone's CS2009 Secures U.S. FDA IND Clearance for Phase II Trial in Advanced Solid Tumours
CStone Pharmaceuticals has received U.S. FDA IND clearance to begin a Phase II trial of its trispecific antibody CS2009 for advanced solid tumours, advancing its global immunotherapy development programme.
Non-Small Cell Lung Cancer | 16/02/2026 | By News Bureau
D3 Bio has received FDA IND clearance to initiate a Phase I trial of its KRAS G12D inhibitor D3S-003 and a Phase II combination study targeting KRAS G12C-mutant lung cancer.
Non-Small Cell Lung Cancer | 19/01/2026 | By News Bureau | 210
Eisai, Nuvation Bio Collaborates to Expand Taletrectinib's Global Reach
The collaboration between Eisai and Nuvation to expand global development and commercialisation of taletrectinib for ROS1-positive non-small cell lung cancer.
Non-Small Cell Lung Cancer | 15/01/2026 | By News Bureau | 121
First Patient Dosed in Phase III Tropian-Lung17 Trial of Datroway in Advanced NSCLC
The global Phase III study evaluates Datroway versus docetaxel in Trop2 NMR-positive advanced nonsquamous NSCLC patients previously treated with immunotherapy and platinum chemotherapy.
Non-Small Cell Lung Cancer | 14/01/2026 | By News Bureau | 107
SystImmune and BMS Present Phase I Results of EGFR x HER3 Bispecific ADC at ESMO 2025
Iza-bren, a potentially first-in-class EGFR x HER3 bispecific Antibody-Drug Conjugate (ADC), is jointly developed by SystImmune and Bristol Myers Squibb under a collaboration and exclusive licence agreement in territories outside of Mainland China.
Non-Small Cell Lung Cancer | 21/10/2025 | By Dineshwori | 218
The enrollment of the first patient in Taiwan extends the recent expansion of the HARMONIC™ trial into Asia, where there is a notably higher prevalence of never-smoker NSCLC patients compared to Western populations.
Non-small Cell Lung Cancer | 10/12/2024 | By Aishwarya | 230
AbbVie Submits BLA to FDA for Teliso-V in Previously Treated Non-Small Cell Lung Cancer
AbbVie has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for accelerated approval of telisotuzumab vedotin (Teliso-V).
Non-small Cell Lung Cancer | 30/09/2024 | By Aishwarya | 434
BerGenBio Partners with Tempus to Accelerate Development in STK11m Non-Small Cell Lung Cancer
BerGenBio's on-going BGBC016 Phase 1b/2a trial is designed to assess the benefit of adding bemcentinib to the current standard of care treatment (immunotherapy + doublet chemotherapy) in 1L STK11m patients, a population with poor outcomes and no specific therapies today.
Non-Small Cell Lung Cancer | 21/08/2024 | By Aishwarya | 497
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy